Related Experiment Video
Updated: Jun 8, 2026
08:08
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Pulmonary hypertension in hemolytic anemias
Shannon Wahl1, Elliott Vichinsky
1Department of Hematology/Oncology, Children's Hospital and Research Center Oakland 747 52nd Street, Oakland, CA 94609 USA.
F1000 Medicine Reports
|October 16, 2010
Summary
Pulmonary hypertension (PH) is linked to hemolytic anemias. Hemolysis-driven endothelial dysfunction is key in sickle cell disease and thalassemia, highlighting the need for clinical trials in PH treatment.
Area of Science:
- Hematology
- Cardiology
- Vascular Biology
Background:
- Pulmonary hypertension (PH) is a recognized complication across inherited and acquired hemolytic anemias.
- Sickle cell disease and thalassemia are prominent examples where PH pathophysiology is increasingly understood.
Purpose of the Study:
- To review the pathophysiology of PH in hemolytic anemias.
- To highlight the role of hemolysis-mediated endothelial dysfunction.
- To emphasize the need for defined treatments and clinical trials.
Main Methods:
- Literature review focusing on pathophysiology of PH in hemolytic anemias.
- Analysis of recent research on sickle cell disease and thalassemia.
- Synthesis of current understanding of hemolysis-mediated endothelial dysfunction.
Main Results:
- Hemolysis-induced endothelial dysfunction is a central mechanism in developing PH in sickle cell disease and thalassemia.
- PH is associated with a significant increase in mortality risk in patients with hemolytic anemia.
Conclusions:
- Understanding the role of hemolysis is crucial for managing PH in hemolytic anemias.
- The optimal treatment for PH in these patients remains undefined.
- Randomized clinical trials are essential to establish effective treatments and improve outcomes.
More Related Videos
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
01:22Portal Hypertension
Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...